How Can We Help You with Your Projects?

Contact us to discuss the specifics of your project. Our team of experienced scientists is ready to assist you with tailored solutions to meet your unique needs. Whether you need help with assay development, FDA IND, stability study, lot release approval, or other scientific endeavors, we are here to support you.Contact us to learn more about our cell based assay services

How Long Does It Take to Get Started?

We will initiate your project as soon as the proposal is approved and signed by you. Our streamlined process ensures a quick start, minimizing delays and maximizing efficiency. Fill out the form below to email us or click our live chat option to speak with a MarinBio Scientist and get your project underway.

Can You Help with Assay Development and Validation for FDA IND, Lot Release and Stability Study Approval?

Yes, we have over 30 years of expertise in developing and validating cell based assays for FDA IND, lot release or stability study approval. Our team can also liaise directly with the FDA on your behalf, ensuring a smooth and compliant process. Please contact us to learn more about how we can assist you with your assay development and FDA approval needs.

Do You Need a Custom or Tailored Assay?

MarinBio scientists are experienced and creative in designing, developing, validating assays. Some of the assays we perform are listed below, but there are many more that we created, developed and validated. Give us call so that we may help you.

Convergence of Immunology and Data Science in Next Generation Cancer Therapy

The emergence of immune checkpoint inhibitors, adoptive cell therapies, and cancer vaccines has underscored the importance of understanding tumor immunobiology at a systems level. Immuno-oncology research increasingly relies on large-scale, multi-modal datasets, including genomics, transcriptomics, proteomics, and spatial data, to characterize tumor environments. Bioinformatics and computational analytics enable the extraction of actionable insights from these datasets, facilitating biomarker discovery, patient stratification, and therapeutic optimization.

Multi-Omics Integration in Immuno-Oncology Discovery

Immuno-oncology (IO) discovery increasingly depends on the coordinated integration of diverse molecular datasets to achieve a systems-level understanding of tumor biology and immune response. Each omics layer captures a distinct aspect of tumor–immune interactions, and when combined, they provide a comprehensive framework for identifying therapeutic targets, biomarkers, and mechanisms of response or resistance.

Table 1. Molecular Layers in Multi-Omics Integration

Omics Layer	Key Data Types	Analytical Outputs	Relevance to Immuno-Oncology
Genomics	Whole exome/genome sequencing	Somatic variants, tumor mutational burden, mutational signatures	Identifies neoantigens, genomic instability, and mutation-driven immune responses
Transcriptomics	Bulk and single-cell RNA-seq	Gene expression signatures, cytokine/chemokine profiles, pathway activation	Defines immune activation states, interferon signaling, and immune-related gene programs
Single-Cell Omics	scRNA-seq, scATAC-seq, multiome	Cell-type identification, lineage trajectories, clonal expansion	Resolves cellular heterogeneity, T cell exhaustion, and rare immune populations
Proteomics	Mass spectrometry, CyTOF, Olink	Protein abundance, post-translational modifications, signaling activity	Measures functional immune states and checkpoint protein expression
Epigenomics	ATAC-seq, ChIP-seq, DNA methylation	Chromatin accessibility, transcription factor binding	Reveals regulatory mechanisms controlling immune cell differentiation and dysfunction
Spatial Profiling	Spatial transcriptomics, multiplex imaging	Tissue architecture, cell localization, spatial interactions	Maps immune infiltration, exclusion, and tumor–immune spatial organization

Integrated Bioinformatics Analysis

Bioinformatics pipelines unify these datasets through multi-modal integration frameworks, enabling cross-validation of biological signals and improved robustness of discoveries. For example, somatic mutations identified through genomics can be linked to transcriptional expression (RNA-seq) and validated at the protein level (proteomics), while spatial data contextualizes where these processes occur within the tumor microenvironment.

This integrative approach supports several key outputs:

Tumor-specific antigens and neoepitopes are identified by combining mutation data with expression and HLA-binding predictions, increasing confidence in true immunogenic targets
Mechanisms of immune evasion emerge through multi-layer analysis, such as loss of antigen presentation (genomics), reduced MHC expression (transcriptomics/proteomics), and immune exclusion (spatial profiling)
Predictive biomarkers are strengthened by integrating orthogonal data types, improving their clinical utility for patient stratification and response prediction

Tumor Microenvironment Characterization

The tumor microenvironment (TME) is a dynamic system composed of tumor cells, immune populations, stromal elements, and extracellular matrix components. Its composition and functional state are major determinants of immunotherapy response.

Computational Approaches to TME Profiling

Computational methods enable both broad and high-resolution characterization of the TME. Bulk transcriptomic data can be deconvoluted using algorithms such as CIBERSORT or TIMER to estimate the relative abundance of immune cell subsets. While these approaches provide valuable population-level insights, single-cell technologies offer a more granular view by directly measuring gene expression at the individual cell level.
Trajectory inference methods applied to single-cell datasets reveal differentiation pathways, such as the progression from naïve to exhausted T cells. In parallel, T cell receptor (TCR) and B cell receptor (BCR) sequencing provides information on clonal expansion and antigen specificity, linking immune cell populations to functional responses.
Cell–cell communication within the TME is further interrogated using ligand–receptor interaction modeling, which identifies signaling networks between tumor cells and immune populations. These analyses are increasingly enhanced by spatial profiling technologies, which preserve tissue architecture and enable mapping of immune cell localization relative to tumor regions.

Neoantigen and Target Discovery

Neoantigens, tumor-specific peptides derived from somatic mutations, are central to many immuno-oncology strategies. Their identification relies on integrated bioinformatics pipelines that combine genomic, immunological, and computational methods.

Table 2: Workflow for Neoantigen Discovery

Step	Methodology	Output	Commonly Used Platform / Website
Variant Calling	WES/WGS using tools such as Mutect2	High-confidence somatic mutations	GATK / Broad Institute – https://gatk.broadinstitute.org
HLA Typing	In silico or experimental HLA typing (e.g., sequencing-based inference tools)	Patient-specific HLA alleles	IEDB Analysis Resource (HLA tools) – https://www.iedb.org
Peptide Generation	In silico translation of mutated sequences into peptide candidates	Candidate neoepitopes	pVACtools (Vanderbilt Neoantigen Pipeline) – https://pvactools.readthedocs.io
MHC Binding Prediction	Algorithms such as NetMHCpan	Binding affinity scores for peptide–MHC interactions	NetMHCpan (DTU Health Tech) – https://services.healthtech.dtu.dk/service.php?NetMHCpan
Immunogen Scoring	Integrated models incorporating expression, processing, and presentation likelihood	Ranked neoantigen candidates	IEDB Immunogenicity & Epitope Prediction Tools – https://www.iedb.org

Applications in Immunotherapy

The identification of high-confidence neoantigens and tumor-associated targets supports multiple therapeutic modalities:

Personalized cancer vaccines, designed to elicit immune responses against patient-specific neoepitopes
Adoptive cell therapies, including TCR-engineered T cells and CAR-T cells targeting tumor antigens
Shared antigen discovery, enabling development of off-the-shelf therapies targeting recurrent mutations or lineage-specific markers

Beyond neoantigens, integrated multi-omics approaches also identify non-mutational targets, such as aberrantly expressed proteins or epigenetically regulated antigens, broadening the landscape of actionable targets in immuno-oncology.

Machine Learning

Machine learning has become a central component of immuno-oncology research, enabling the extraction of predictive and mechanistic insights from high-dimensional, heterogeneous biological datasets. These approaches are particularly valuable for identifying biomarkers of response, characterizing tumor–immune interactions, and supporting therapeutic development across discovery and clinical stages.

Table 3. Machine Learning Approaches in Immuno-Oncology

Approach	How It Works	What Information It Provides	How It Is Used in Immuno-Oncology Therapy
Supervised Learning	Trains on datasets where inputs (e.g., gene expression, biomarkers) are paired with known outcomes (e.g., responder vs. non-responder), learning patterns to predict outcomes in new patients	Predictive outputs such as probability of response, survival likelihood, or biomarker importance	Used to predict which patients will respond to therapies like checkpoint inhibitors, support patient stratification, and identify clinically relevant biomarkers (e.g., PD-L1, TMB)
Unsupervised & Representation Learning	Analyzes unlabeled data to find natural groupings (clustering) or compress data into meaningful features (embeddings) based on similarity	Reveals hidden structure such as tumor subtypes, immune phenotypes, or key biological patterns	Used to discover new cancer subtypes, identify immune “hot” vs. “cold” tumors, and uncover novel therapeutic targets or mechanisms of resistance
Deep Learning in Multi-Modal Data Integration	Uses neural networks to combine multiple data types (e.g., genomics, imaging, clinical data) into a unified model that captures complex relationships	Integrated insights across data types, improving prediction accuracy and capturing interactions between biological systems	Used to improve prediction of treatment response by combining diverse datasets, enhance patient stratification, and support precision medicine by considering the full tumor-immune context
Generative Models	Learns the underlying distribution of data and generates new synthetic data points or simulations (e.g., via GANs or VAEs)	Produces simulated datasets, novel molecular designs, or hypothetical biological scenarios	Used to generate synthetic patient or tumor data to augment limited datasets, simulate drug responses, and design or optimize new immunotherapies (e.g., antibody or neoantigen discovery)

In practice, these approaches are often used together in immuno-oncology. Supervised learning drives clinical decision-making by predicting therapy response, while unsupervised methods help define the biological landscape of tumors. Deep learning enables integration of complex, multi-modal datasets for more accurate and holistic predictions, and generative models extend data and explore new therapeutic possibilities. Together, they form a complementary toolkit for advancing precision immunotherapy.

Advanced Analytics and Systems Modeling in Immuno-Oncology

Advanced analytics and systems modeling approaches are essential for moving beyond descriptive analyses toward mechanistic understanding and predictive simulation of tumor–immune interactions. These methods integrate multi-omics, clinical, and temporal data to reconstruct biological networks, quantify dynamic changes, and support rational therapeutic design.

Table 4. Advanced Modeling Approaches

Approach	How It Works	What Information It Provides	How It Is Used for Immuno-Oncology Therapy
Network and Pathway Analysis	Maps genes, proteins, and signaling molecules into interaction networks and biological pathways, then analyzes how they change under different conditions	Identifies key pathways, hub genes, and interaction networks driving tumor–immune behavior	Used to pinpoint dysregulated immune pathways (e.g., interferon signaling), identify drug targets, and understand mechanisms of response or resistance to immunotherapy
Longitudinal and Time-Series Analysis	Tracks patient or biological data over time (e.g., before, during, after treatment) and models how variables change dynamically	Reveals temporal patterns such as immune activation, tumor evolution, and treatment response trajectories	Used to monitor treatment response, detect early signs of relapse or resistance, and optimize treatment timing or sequencing in immunotherapy
Causal Inference and Mechanistic Modeling	Uses statistical and mathematical models to distinguish cause-and-effect relationships rather than simple correlations; often incorporates biological knowledge	Identifies which factors truly drive outcomes and predicts the impact of interventions	Used to determine whether biomarkers (e.g., PD-L1) directly influence response, guide target selection, and simulate how modifying pathways will affect therapeutic outcomes
Digital Twins and In Silico Trials	Creates computational models of individual patients or populations that simulate disease progression and treatment response	Provides personalized predictions of treatment outcomes and virtual trial results	Used to simulate how a specific patient might respond to different immunotherapies, optimize dosing strategies, and reduce reliance on costly or time-consuming clinical trials

In practice, these approaches provide deeper biological and clinical insight beyond standard prediction models. Network and pathway analysis helps researchers understand the underlying biology driving immune responses and identify actionable drug targets. Longitudinal analysis adds a time dimension, allowing clinicians to track how patients respond and adapt treatment strategies in real time. Causal inference moves beyond correlation to determine what truly drives therapeutic outcomes, which is critical for selecting effective targets and avoiding misleading biomarkers. Digital twins and in silico trials take this a step further by simulating patient-specific responses, enabling more precise, personalized treatment decisions and accelerating drug development with fewer real-world experiments.

Applications in Drug Discovery and Development

Advanced computational approaches, including bioinformatics, machine learning, and systems-level analytics are increasingly integrated throughout the immuno-oncology (IO) drug discovery and development pipeline. These methods enable more efficient identification of therapeutic targets, improved patient stratification, and more predictive clinical trial design.

Target Identification and Validation

Bioinformatics and machine learning approaches are central to identifying biologically and clinically relevant targets in immuno-oncology by integrating genomic, transcriptomic, proteomic, and clinical datasets. Key applications include the discovery of novel immune checkpoints involved in T cell exhaustion, myeloid suppression, and innate immune regulation. In addition, integrated genomic and transcriptomic analyses enable identification of tumor-specific antigens arising from somatic mutations, gene fusions, or aberrant expression patterns that are selectively expressed in tumor cells but absent in normal tissues.Machine learning models can rank candidate targets based on combined evidence of immunological relevance, druggability, and clinical association, enabling more efficient selection of high-confidence therapeutic targets.

Biomarker Development

Biomarker development in immuno-oncology relies on computational methods to identify molecular and cellular features that predict therapeutic response, resistance, and toxicity. These biomarkers are essential for precision medicine strategies and are increasingly integrated into clinical trial design. Predictive biomarkers such as tumor mutational burden (TMB) reflect the overall neoantigen load and are associated with likelihood of response to immune checkpoint blockade. Gene expression signatures, provide insights into pre-existing immune activation states within the tumor microenvironment.

Similarly, immune cell infiltration metrics, derived from bulk RNA-seq deconvolution or spatial profiling, quantify the presence and spatial organization of effector and suppressive immune populations. Beyond single biomarkers, composite multi-parametric signatures are increasingly used to improve predictive accuracy. These may integrate genomic instability measures, immune gene expression programs, and spatial immune architecture into unified scoring systems. Machine learning models are often employed to derive and validate these signatures across independent cohorts.

Clinical Trial Design

Advanced analytics are transforming clinical trial design in immuno-oncology by enabling more efficient, adaptive, and data-driven trial structures. These approaches improve the probability of trial success while reducing cost, time, and patient burden.

Patient stratification is enhanced through integration of molecular, clinical, and imaging data to define biologically homogeneous subgroups. This allows enrichment of trial populations based on predictive biomarkers such as TMB, PD-L1 expression, or immune gene signatures, thereby increasing the likelihood of detecting treatment effects.

Adaptive trial designs leverage interim data analysis to dynamically modify key trial parameters, such as dose levels, cohort sizes, or treatment arms. Machine learning models can support these designs by continuously updating predictions of response probability and toxicity risk based on incoming patient data. Endpoint prediction models are also increasingly used to link early biological signals (e.g., immune activation markers, circulating tumor DNA dynamics) with long-term clinical outcomes such as progression-free survival (PFS) and overall survival (OS). This enables earlier assessment of therapeutic efficacy and may accelerate decision-making in drug development.

Table 5. Advanced Analytics in Clinical Trial Design

Trial Optimization	Computational Approach	Impact
Patient stratification	Biomarker integration + ML clustering	Improved response rates and trial efficiency
Adaptive design	Bayesian models, reinforcement learning	Flexible, data-driven trial modification
Endpoint modeling	Predictive modeling of surrogate endpoints	Faster evaluation of clinical benefit

Computational and data-driven approaches are deeply embedded across the immuno-oncology drug discovery and development continuum. From target identification and biomarker discovery to cell therapy engineering and adaptive clinical trial design, these methods enable more precise, efficient, and predictive therapeutic development strategies.

Conclusion

Bioinformatics, modern data platforms, machine learning, and advanced analytics are now foundational to immuno-oncology research and drug discovery. These approaches enable comprehensive characterization of the tumor–immune interface, identification of actionable targets, and development of predictive models for therapeutic response. As technologies evolve, integration of multi-modal data, improved model interpretability, and robust validation frameworks will be critical for translating computational insights into clinical impact. The continued convergence of computational science and immunology holds significant promise for accelerating the development of more effective, personalized cancer immunotherapies.

Image credit: Portions of the figure in this article may be generated using ChatGPT (OpenAI) or Google Gemini.

Disclaimer: This blog post is intended solely for educational and scientific informational purposes. Any mention of therapeutic drug names, including FDA-approved medications, is for the purpose of accurate reporting and discussion of biomedical research and does not constitute medical advice, endorsement, or promotion. Readers should not interpret the content as a recommendation for any specific treatment. Always consult a qualified healthcare professional for medical advice or treatment decisions.

About Marin Biologic Laboratories

Our Recent Publication/Meeting Presentation on Gene Therapy

1. Development of VNX-101, an Adeno-Associated Virus with Less Immunogenicity and Efficient Long-Term Expression of a CD19 T-Cell Engager. Molecular Therapy Methods & Clinical Development, published online July 24, 2025.

2. Cell-Based Potency Assay for Anti-CD3-Anti-CD19 Diabody. Journal of Immunological Methods. 2025. 545-114004.

3. Development of a Pharmacokinetic (PK) Mouse Serum GLP ELISA for an Anti–CD19–AntiCD3 Diabody
bioRxiv 2025.03.19.644217; doi: https://doi.org/10.1101/2025.03.19.644217.

4. American Society of Hematology (ASH) Annual Meeting 2024.
Abstract link: Using Gene Therapy to Solve Challenges with CAR-T Cell Immunotherapy: Lead Selection and Preclinical Development of an Adeno-Associated Virus with Reduced Immunogenicity Exhibiting Efficient and Long-Term Expression of an Anti-CD19 T-Cell Engager.

Comprehensive Assay Solutions for In Vitro and Cell Based Potency Assays and Pharmacokinetics Studies- Our Expertise

With 30 years of expertise in cell culture, cell-based assays, and preclinical/clinical PK/PD analysis, we specialize in offering assay services essential for a wide variety of therapeutic drug development programs, preclinical studies, IND/BLA applications, and commercialization. Our comprehensive services include both preclinical non-GLP and GLP assays, as well as non-GMP and GMP assays, providing critical support throughout the entire development pipeline.

Watch the following video and explore our latest presentation on the development and validation of potency and pharmacokinetic (PK) assays for AAV vectors, highlighting innovative methodologies and industry-leading expertise.